Carol Ann Huff, MD

Articles by Carol Ann Huff, MD

Interpreting MajesTEC-3 Efficacy in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 8th 2026

Role of Bispecific Antibodies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 8th 2026

Unmet Needs in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

March 31st 2026

Defining Early Relapse and Treatment Selection in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

March 31st 2026

Follow-up Care for Cancer: Making the Benefits Equal the Cost

ByCarol Ann Huff, MD,Michael Carducci, MD,Nancy E. Davidson, MD

October 1st 2000

The premise that early diagnosis of certain types of malignancies improves outcome and survival is a cornerstone of modern medicine. Routine use of the Pap smear has been associated with reduced mortality from cervical cancer. Randomized trials

Latest Updated Articles

Follow-up Care for Cancer: Making the Benefits Equal the Cost
October 1st 2000

Carol Ann Huff, MD

Articles by Carol Ann Huff, MD

Interpreting MajesTEC-3 Efficacy in Multiple Myeloma

Role of Bispecific Antibodies in Multiple Myeloma

Unmet Needs in Early Relapse Multiple Myeloma

Defining Early Relapse and Treatment Selection in Multiple Myeloma

Follow-up Care for Cancer: Making the Benefits Equal the Cost

Latest Updated Articles

Trending on CancerNetwork

FDA Issues Second CRL for RP1/Nivolumab in Advanced Melanoma

AI-Driven Risk Assessment is Transforming Breast Cancer Screening

FDA Lifts Partial Clinical Hold on Lorigerlimab for Gynecologic Cancer

Targeting the Tumor Ecosystem to Create Pan–Solid Tumor Vulnerability

FDA Clears At-Home HPV Self-Collection Kit to Expand Cervical Cancer Screening Access